Recently,\u00a0Sinotau Pharmaceutical Group announced it has closed an 320 million RMB D+ financing, which was jointly invested by\u00a0China Life Private Equity\u00a0and\u00a0Centurium Capital, and continued to be followed by the existing shareholders,\u00a0Tianjin Panya Equity Investment Fund\u00a0Partnership(L.P.)\u00a0and\u00a0Deyi Investment Management (Beijing)\u00a0Co., Ltd., and a lot of help and support from WinX Capital.
\n\u00a0
\nPreviously, in February 2021, Sinotau just completed a D financing led by CICC Capital, followed by a series of institutions, and supported by the original institutional shareholders such as Lotus Lake Capital. In less than one and a half years since April 2020, Sinotau has completed\u00a0consecutive\u00a0financing totaling\u00a0approximately\u00a01 billion RMB, fully\u00a0demonstrating\u00a0the capital market’s\u00a0high recognition of\u00a0Sinotau’s strong\u00a0radiopharmaceutical innovation R&D\u00a0capability. The funds raised will continue to be used for clinical\u00a0R&D\u00a0of new radiopharmaceutical projects.
\n\u00a0
\nSinotau is an innovative\u00a0pharmaceutical company\u00a0focusing on the R&D, production and clinical application of new generation radiopharmaceuticals, with an\u00a0extensive\u00a0product line of radioactive targeted\u00a0integration of diagnosis and\u00a0therapy.
\n\u00a0
\nSinotau,\u00a0headquartered in Beijing,\u00a0has\u00a0modern radiopharmaceutical\u00a0manufacturing\u00a0bases in Jiangsu, Guangdong and Sichuan, and a branch office in the U.S.\u00a0Relying on the world’s leading R&D resources in the field of radiopharmaceuticals and precise diagnosis and therapy, Sinotau has taken the lead in laying out a number of targeted therapeutic and precise diagnostic radiopharmaceuticals in the fields of oncology,\u00a0neurodegenerative diseases\u00a0and\u00a0cardiovascular diseases.\u00a0Relying on the strong R&D capability of its own R&D team, Sinotau’s\u00a0product\u00a0pipeline has now laid out a number of\u00a0radiopharmaceuticals,\u00a0some of which\u00a0have entered the\u00a0registered\u00a0clinical research stage.
\n\u00a0
\nWith the targeted clinical application of\u00a0radioisotopes\u00a0in recent years,\u00a0the\u00a0global\u00a0radiopharmaceutical\u00a0market\u00a0size\u00a0is growing rapidly, which was $7.1 billion in 2020 and is expected to reach $26 billion in 2030. Meanwhile, with the\u00a0release\u00a0of domestic programmatic industry documents, the application of radiopharmaceuticals to the\u00a0Marketing\u2002Authorization\u2002Holder\u2002(MAH)\u2002system, and the\u00a0liberalization\u00a0of\u00a0radiopharmaceutical\u00a0equipment configuration certificates, the domestic radiopharmaceutical market will also get vigorous development.
\n\u00a0
\n\u00a0\u201cWith the introduction of the national medium and long-term development plan in the field of radiopharmaceuticals, the development of the domestic radiopharmaceutical field has started to enter the fast lane,\u201d said\u00a0Mr. Xu Xinsheng, founder and chairman of Sinotau.\u00a0\u201cThe field of radiopharmaceuticals\u00a0in China is still in the early stage of development. Sinotau relies on strong independent\u00a0R&D\u00a0capabilities, while cooperating with international advanced radiopharmaceutical companies to fully\u00a0promote\u00a0the\u00a0R&D\u00a0of radiopharmaceuticals, providing sufficient\u00a0ammunition\u00a0for patients and colleagues in radiopharmaceuticals. We believe that with the help of high-quality capital and the\u00a0joint efforts\u00a0of our partners, we will make Sinotau a leading company in the field of radiopharmaceuticals in China and contribute to the rise of China’s radiopharmaceutical industry.
\n\u00a0
\n“Sinotau is one of the few biopharmaceutical companies in China that has the ability to\u00a0research and\u00a0develop both nuclear medicine and innovative targeted precursors, and has\u00a0accumulated\u00a0rich experience in R&D, manufacturing, clinical trials and registration filings of radiopharmaceuticals, with a product pipeline covering both innovative diagnostic radiopharmaceutical and therapeutic radiopharmaceutical, and outstanding comprehensive capabilities in the industry,\u201d\u00a0said Ms.\u00a0Zhang\u00a0Redie, responsible\u00a0person\u00a0of\u00a0the\u00a0China Life Private Equity.\u00a0\u201cChina Life\u00a0Private Equity\u00a0expects to help Sinotau continue to innovate in the field of radiopharmaceuticals\u00a0and accelerate the commercialization of clinically-needed diagnostic and therapeutic radiopharmaceutials, thereby meeting the growing health needs of the people.”
\n\u00a0
\n\u201cAfter years of exploration and\u00a0accumulation,\u00a0Sinotau has established high\u00a0barriers\u00a0in the radiopharmaceutical field from\u00a0upstream\u00a0supply of nuclides to downstream clinical applications, and has laid\u00a0a solid foundation\u00a0in product layout, upstream and downstream cooperation and team building, ” said Mr. Chen Zhixing,\u00a0managing director\u00a0of\u00a0the\u00a0Centurium Capital.\u00a0\u201cIn comparison with\u00a0overseas markets,\u00a0the domestic radiopharmaceutical industry has\u00a0considerable\u00a0growth potential. We recognize the\u00a0uniqueness\u00a0and\u00a0preemptive\u00a0localization\u00a0of Sinotau in the radiopharmaceutical field in China and look forward to this financing to drive the company’s further development and\u00a0ultimately\u00a0benefit more patients.”
\n\u00a0
\n“As a leading company of innovative radiopharmaceuticals in China, Sinotau is\u00a0based on rich global technology resources and advanced independent\u00a0R&D\u00a0capabilities,\u201d\u00a0said Mr. Zou Guowen, founder of WinX Capital. ” WinX Capital believes that Sinotau will drive the rise of China’s innovative radiopharmaceutical market in the future, and at the same time go out of China to\u00a0showcase itself\u00a0in the international market.”<\/p>\n","protected":false},"excerpt":{"rendered":"
Recently,\u00a0Sinotau Pharmaceutical Group announced it has closed an 320 million RMB D+ financing, which was jointly invested by\u00a0China Life Private Equity\u00a0and\u00a0Centurium Capital, and continued to be followed by the existing shareholders,\u00a0Tianjin Panya Equity Investment Fund\u00a0Partnership(L.P.)\u00a0and\u00a0Deyi Investment Management (Beijing)\u00a0Co., Ltd., and a lot of help and support from WinX Capital. \u00a0 Previously, in February 2021, Sinotau […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-3796","post","type-post","status-publish","format-standard","hentry","category-company-news"],"meta_box":[],"_links":{"self":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/comments?post=3796"}],"version-history":[{"count":1,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3796\/revisions"}],"predecessor-version":[{"id":3797,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3796\/revisions\/3797"}],"wp:attachment":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/media?parent=3796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/categories?post=3796"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/tags?post=3796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}